PDF(Pubmed)
Abstract：
High sugar consumption is associated with cardiovascular diseases and diabetes. Current sugar substitutes may cause taste sensations and gastrointestinal symptoms. ENSO 16 is a combination of 16 different sugar substitutes and plant fibers and has been designed as a sugar alternative. The impact on plasma glucose metabolism as well as on gastrointestinal tolerance has not been investigated yet. 17 healthy participants were enrolled in this randomized, double-blind trial. Participants received a single oral dose of 30 g glucose or 30 g ENSO 16 and crossed over to the alternate treatment after a 7 day wash out period. The study endpoint was the effect on plasma glucose, insulin, C-peptide concentrations and gastrointestinal disorders. A questionnaire regarding gastrointestinal symptoms was used for individual subjective scoring. The mean baseline adjusted plasma glucose AUC0-180 min was significantly greater after glucose administration compared to ENSO 16 (n = 15, p = 0.0128, paired t-test). Maximum plasma glucose elevation over baseline was 117 mg*dl-1 and 20 mg*dl-1 after oral glucose or ENSO 16, respectively. Insulin and C-peptide AUC0-180 min were significantly greater after glucose compared to ENSO 16 intake (p < 0.01, Wilcoxon rank sum test). The mean maximal concentrations of plasma glucose, insulin and C-peptide after glucose intake were 1.5, 4.6 and 2.7-fold greater after glucose intake compared to ENSO 16 intake, respectively. Adverse reactions were mostly mild and not different between treatments. Conclusion. ENSO 16 has only a small impact on plasma glucose metabolism. This may be of interest in a dietary context and may help to reduce calory intake.Trail registration NCT05457400. First registration: 14/07/2022. https://clinicaltrials.gov/study/NCT05457400 .
摘要：
高糖消耗与心血管疾病和糖尿病有关。目前的糖替代品可能会引起味觉和胃肠道症状。ENSO16是16种不同的糖替代品和植物纤维的组合，已被设计为糖替代品。尚未研究对血浆葡萄糖代谢以及对胃肠道耐受性的影响。17名健康参与者参加了这项随机研究，双盲审判.参与者接受30g葡萄糖或30gENSO16的单次口服剂量，并在7天的冲洗期后交叉进行替代治疗。研究终点是对血浆葡萄糖的影响，胰岛素，C肽浓度和胃肠道疾病。使用有关胃肠道症状的问卷进行个人主观评分。与ENSO16相比,施用葡萄糖后平均基线调整的血浆葡萄糖AUC0-180分钟显著更大(n=15,p=0.0128,配对t检验)。口服葡萄糖或ENSO16后，相对于基线的最大血浆葡萄糖升高分别为117mg*dl-1和20mg*dl-1。与ENSO16摄入相比,在葡萄糖后,胰岛素和C肽AUC0-180分钟显著更大(p<0.01,Wilcoxon秩和检验)。血浆葡萄糖的平均最大浓度，与ENSO16摄入量相比，摄入葡萄糖后的胰岛素和C肽分别为摄入葡萄糖后的1.5、4.6和2.7倍，分别。不良反应大多轻微，治疗之间没有差异。结论。ENSO16对血浆葡萄糖代谢只有很小的影响。这在饮食环境中可能是有意义的,并且可能有助于减少卡路里的摄入。步道注册NCT05457400。首次注册：2022年7月14日。https://clinicaltrials.gov/study/NCT05457400.
